search
Back to results

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma (NATARS)

Primary Purpose

Retroperitoneal Sarcoma

Status
Enrolling by invitation
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Radical Surgery
Sponsored by
Peking University International Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Retroperitoneal Sarcoma focused on measuring Retroperitoneal Sarcoma, Neoadjuvant therapy, Target therapy, Survival

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically proven primary high-risk Retroperitoneal sarcoma(RPS) (Including Dedifferentiated liposarcoma (DDLPS), leiomyosarcoma(LMS), Undifferentiated pleomorphic sarcoma(UPS), Solitary fibrous tumor(SFT)). Primary localized RPS without histories of surgical resection, chemo- or radio-therapy, targeted therapy. Patients who underwent laparotomy with biopsy only will also be considered as primary cases. Without histories of second malignant tumors. In DDLPS Diagnosis should be confirmed based on MDM2(Mouse double minute 2 homolog) and CDK4(Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while MDM2 amplification in the Fish test is highly recommended. All grade 2-3 DDLPS can be included. In LMS All grades of LMS can be included. Tumor size ≥10cm In UPS or SFT All grades of UPS can be included. High-risk SFT with a score ≥6 in 'Risk stratification of SFT for development of metastasis' introduced in The 5th edition of the WHO(World Health Organization) Soft tissue sarcoma classification. Sarcoma without protruding across the diaphragm Possibility of R0/R1 resection evaluated through preoperative MDT(multi-disciplinary team) discussion No multi-organ or system dysfunction/failure or patients with slight dysfunction of organ/system could be easily recovered Tolerable of chemotherapy and surgery through MDT evaluation and tests. American Society of Anesthesiologist (ASA) ≤3 Fully understand the informs and consent to participate in the study. Exclusion Criteria: Sarcoma confirmed originating from the GI tract, uterus, or urinal tract. Patients included in the study through preoperative biopsy or MDT discussion, with WDLPS, grade 1 LPS, or other types of tumors not mentioned in the Inclusion criteria evaluating through final pathological findings. Sarcoma protruded into the chest cavity evaluated through preoperative imaging or surgical reports. Metastasis confirmed pathologically or highly suspicious metastatic lesions through radiological findings, PET-CT(Positron emission tomography) is highly recommended, MDT discussion and evaluation are needed. Histories of administration of Anthracyclines, Ifosfamide, and targeted agents. Severe contradiction to surgery and chemotherapies, including persistent myelosuppression, myocardial/cerebral/pulmonary infarction, uncontrolled cardiac arrhythmia, etc within the last 6 months Indication of severe infection or undergoing surgeries with high-risk hemorrhages in one month. Persistent one or more organ or system dysfunctions, could not be recovered prior to the study. Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control methods. Patients with psychological conditions

Sites / Locations

  • Beijing Friendship Hospital
  • Peking University First Hospital
  • The Affiliated Hospital of Qingdao University
  • Shanghai Cancer Hospital, Minhang Branch
  • Shanghai Zhongshan Hospital
  • First Affiliated Hospital Xi'an Jiaotong University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

The Neoadjuvant Therapy Group

The Surgery only Group

Arm Description

Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin(PLD) 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks * 3 Circles, Watch-Wait 4-6 weeks

Procedure: Radical resectional surgery

Outcomes

Primary Outcome Measures

3-year Progression Free Survival(PFS)
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.

Secondary Outcome Measures

1-year PFS
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
1 year Overall survival(OS)
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
3-year OS
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
5-year PFS
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
5-year OS
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
Safety and toxicity of neoadjuvant therapy
Safety and toxicity will be evaluated through blood tests, echocardiography, ECG, etc.
Postoperative morbidities
Operative outcomes including morbidities will be collected and compared in two groups.

Full Information

First Posted
April 16, 2023
Last Updated
May 11, 2023
Sponsor
Peking University International Hospital
Collaborators
Shanghai Zhongshan Hospital, The Affiliated Hospital of Qingdao University, Peking University First Hospital, Shanghai Cancer Hospital, China, First Affiliated Hospital Xi'an Jiaotong University, Beijing Friendship Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05844813
Brief Title
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
Acronym
NATARS
Official Title
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
November 1, 2025 (Anticipated)
Study Completion Date
November 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University International Hospital
Collaborators
Shanghai Zhongshan Hospital, The Affiliated Hospital of Qingdao University, Peking University First Hospital, Shanghai Cancer Hospital, China, First Affiliated Hospital Xi'an Jiaotong University, Beijing Friendship Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma. The main questions it aims to answer are: Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group. The Overall survival time in the two groups. The safety and tolerance in the neoadjuvant therapy group. Participants will be allocated into two groups once they meet the inclusion criteria. Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy. Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retroperitoneal Sarcoma
Keywords
Retroperitoneal Sarcoma, Neoadjuvant therapy, Target therapy, Survival

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
It is a prospective non-randomized controlled study. After meeting the inclusion and exclusion criteria, patients will be allocated either into the Surgery-only Group or the Neoadjuvant therapy group. Patients in the surgery-only group will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy, while in the neoadjuvant therapy group, patients will receive neoadjuvant chemotherapy combined with target treatment for three circles followed by the sarcoma resectional surgeries.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
102 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The Neoadjuvant Therapy Group
Arm Type
Experimental
Arm Description
Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin(PLD) 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks * 3 Circles, Watch-Wait 4-6 weeks
Arm Title
The Surgery only Group
Arm Type
Active Comparator
Arm Description
Procedure: Radical resectional surgery
Intervention Type
Drug
Intervention Name(s)
Doxorubicin+Ifosfamide+Anlotinib(AI+A)
Intervention Description
Doxorubicin(PLD) 40mg/㎡ d1, Ifosfamide(I) 1g/㎡ d1-5, Anlotinib(A)10mg d1-14 Q3weeks * 3 Circles
Intervention Type
Procedure
Intervention Name(s)
Radical Surgery
Intervention Description
Radical sarcoma resectional surgery
Primary Outcome Measure Information:
Title
3-year Progression Free Survival(PFS)
Description
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
Time Frame
3 years after first patient enrolled in
Secondary Outcome Measure Information:
Title
1-year PFS
Description
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
Time Frame
1year after first patient enrolled in.
Title
1 year Overall survival(OS)
Description
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
Time Frame
1year after first patient enrolled in
Title
3-year OS
Description
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
Time Frame
3 years after first patient enrolled in
Title
5-year PFS
Description
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
Time Frame
5 years after first patient enrolled in.
Title
5-year OS
Description
OS will be measured from the date of surgery to the date of death, whatever the causes of death.
Time Frame
5 years after first patient enrolled in
Title
Safety and toxicity of neoadjuvant therapy
Description
Safety and toxicity will be evaluated through blood tests, echocardiography, ECG, etc.
Time Frame
1-d, 7-d after the first date of each neoadjuvant therapy session.
Title
Postoperative morbidities
Description
Operative outcomes including morbidities will be collected and compared in two groups.
Time Frame
30-d, 90-d, 1-year separately after the date of surgery.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically proven primary high-risk Retroperitoneal sarcoma(RPS) (Including Dedifferentiated liposarcoma (DDLPS), leiomyosarcoma(LMS), Undifferentiated pleomorphic sarcoma(UPS), Solitary fibrous tumor(SFT)). Primary localized RPS without histories of surgical resection, chemo- or radio-therapy, targeted therapy. Patients who underwent laparotomy with biopsy only will also be considered as primary cases. Without histories of second malignant tumors. In DDLPS Diagnosis should be confirmed based on MDM2(Mouse double minute 2 homolog) and CDK4(Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while MDM2 amplification in the Fish test is highly recommended. All grade 2-3 DDLPS can be included. In LMS All grades of LMS can be included. Tumor size ≥10cm In UPS or SFT All grades of UPS can be included. High-risk SFT with a score ≥6 in 'Risk stratification of SFT for development of metastasis' introduced in The 5th edition of the WHO(World Health Organization) Soft tissue sarcoma classification. Sarcoma without protruding across the diaphragm Possibility of R0/R1 resection evaluated through preoperative MDT(multi-disciplinary team) discussion No multi-organ or system dysfunction/failure or patients with slight dysfunction of organ/system could be easily recovered Tolerable of chemotherapy and surgery through MDT evaluation and tests. American Society of Anesthesiologist (ASA) ≤3 Fully understand the informs and consent to participate in the study. Exclusion Criteria: Sarcoma confirmed originating from the GI tract, uterus, or urinal tract. Patients included in the study through preoperative biopsy or MDT discussion, with WDLPS, grade 1 LPS, or other types of tumors not mentioned in the Inclusion criteria evaluating through final pathological findings. Sarcoma protruded into the chest cavity evaluated through preoperative imaging or surgical reports. Metastasis confirmed pathologically or highly suspicious metastatic lesions through radiological findings, PET-CT(Positron emission tomography) is highly recommended, MDT discussion and evaluation are needed. Histories of administration of Anthracyclines, Ifosfamide, and targeted agents. Severe contradiction to surgery and chemotherapies, including persistent myelosuppression, myocardial/cerebral/pulmonary infarction, uncontrolled cardiac arrhythmia, etc within the last 6 months Indication of severe infection or undergoing surgeries with high-risk hemorrhages in one month. Persistent one or more organ or system dysfunctions, could not be recovered prior to the study. Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control methods. Patients with psychological conditions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chenghua Luo, MD, PhD
Organizational Affiliation
Peking University International Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Friendship Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Peking University First Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Facility Name
Shanghai Cancer Hospital, Minhang Branch
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
Shanghai Zhongshan Hospital
City
Shanghai
State/Province
Shanghai
Country
China
Facility Name
First Affiliated Hospital Xi'an Jiaotong University
City
Xi'an
State/Province
Shanxi
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

We'll reach out to this number within 24 hrs